Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: Clinical implications

British Journal of Cancer

Volumn 87, Issue 10, 2002, Pages 1145-1152

  Ferrandina, G ^a   Lauriola, L ^a   Zannoni, G F ^a   Distefano, M G ^a   Legge, F ^a   Salutari, V ^a   Gessi, M ^a   Maggiano, N ^a   Scambia, G ^a   Ranelletti, F O ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cervical cancer; Chemotherapy response; COX 2; Prognosis

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOOXYGENASE 2; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; TRYPTASE;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANTIBODY DETECTION; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAJOR CLINICAL STUDY; MAST CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STROMA; SURVIVAL RATE; TISSUE SECTION; UTERINE CERVIX CANCER;

ADULT; AGED; ANIMALS; ANTIGENS, CD; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; ISOENZYMES; MEMBRANE PROTEINS; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RABBITS; STROMAL CELLS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 18744404489     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600578     Document Type: Article

References (29)

1. Benedetti-Panici P, Maneschi F, Cutillo G, Greggi S, Salerno MG, Amoroso M, Scambia G, Mancuso S (1996) Modified type IV-V radical hysterectomy with systematic pelvic and aortic lymphadenectomy in the treatment of patients with stage III cervical carcinoma. Feasibility, technique and clinical results. Cancer 78: 2359-2365
2. Bribiesca-Benitez L, Wong A, Utrera D, Castellanos E (2001) The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 49: 1061-1062
3. Chao HT, Wang PH, Tseng JY, Lai CR, Chiang SC, Yuan CC (1999) Lymphocyte-infiltrated FIGO Stage IIB squamous cell carcinoma of the cervix is a prominent factor for disease-free survival. Eur J Gynecol Oncol 2: 136-140
4. Cox DR (1970) Analysis of Binary Data. London: Methven
5. Cox DR (1972) Regression models and life tables. J Royal Statist Soc 34: 197-220
6. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G (2002a) Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patient. Ann Oncol 13: 1205-1211
7. Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO (2002b) Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20: 973-981
8. Gaffney DK, Holden J, Zempolichi K, Murphy KJ, Dicker AP, Dodson M (2001) Elevated cyclooxygenase-2 expression in cervical carcinoma. Reduced cause-specific survival and pelvic control. Am J Clin Oncol 24: 413-416
9. Hundley TR, Prasad AR, Beaven MA (2001) Elevated levels of Cyclooxygenase-2 in antigen-stimulated mast cells is associated with minimal activation of p38 mitogen-activated protein kinase. J Immunol 167: 1629-1636
10. Iniguez MA, Punzon C, Fresno M (1999) Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclooxygenase inhibitors. J Immunol 163: 111-119
11. Kankkunen J, Harvima I, Naukkariner A (1997) Quantitative analysis of tryptase and chymase containing mast cells in benign and malignant breast lesions. Int J Cancer 72: 385-388
12. Kaplan E, Meyer P (1958) Non parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481
13. Lehay KM, Ornberg RL, Wang Y, Zwifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase 2 inhibition by Celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631
14. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
15. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311
16. Prescott SM (2000) Is cyclooxygenase-2 the alpha and the omega in cancer? Clin Invest 105: 1511-1513
17. Ranelletti FO, Almadori G, Rocca B, Ferrandina G, Ciabattoni G, Habib A, Galli J, Maggiano N, Gessi M, Lauriola L (2001) Prognostic significance of cyclooxygenase-2 expression in laryngeal squamous cell carcinoma. Int J Cancer 95: 343-349
18. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635
19. Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PC (2001) Tumour-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumour draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Gynecol Oncol 81: 424-432
20. Snyderman M (2001) Biologically useful responses of human neoplasia to Celecoxib and Lovastatin. Proceedings of the American Society of Clinical Oncology (abstract) San Francisco, May 2001
21. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronemberg M, Miller PW, Portanova J, Lee JC, Dubinett SM (2000) Specific inhibition of cyclooxygenase-2 restores antitumour reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370
22. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama S, Osada T, Salto S, Tsuruo T, Shibata Y, Nagawa H (2000) Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis of colorectal cancer. Br J Cancer 83: 324-328
23. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501
24. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase-2 regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716
25. Williams CS, DuBois RN (1996) Prostaglandins endoperoxide synthase: Why two isoforms? Am J Physiol 270: 393-400
26. Williams CS, Tsujii M, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594
27. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO, Geneva 1979 Offset publication no. 48 16-21
28. Yamada T, Sawatsubashi M, Yakushji H, Itoh Y, Edakuni G, Mori M, Robert L, Miyazaki K (1998) Localization of vascular endothelial growth factor in synovial membrane mast cells: Examination with 'multi-labelling subtraction immunostaining'. Virchows Arch 433: 567-570
29. Zeid NA, Muller HK (1993) S100 Positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25: 338-343